Jaquet P, Hassoun J, Delori P, Gunz G, Grisoli F, Weintraub B D
J Clin Endocrinol Metab. 1984 Nov;59(5):817-24. doi: 10.1210/jcem-59-5-817.
A 43-yr-old woman, who had previously had a subtotal thyroidectomy, presented with hyperthyroidism and amenorrhea-galactorrhea due to a pituitary adenoma secreting TSH, TSH-alpha, and PRL. Her serum T4 concentration was 14 micrograms/dl; T3, 5.7 ng/ml, and TSH, 19-33 microU/ml. Serum TSH was not altered by TRH stimulation or T3 suppression. Basal plasma PRL levels were 19-27 ng/ml and plasma PRL doubled after TRH stimulation. A 900-mg pituitary tumor, removed by transphenoidal surgery, was studied in cell culture. After dispersion, tumor cells were maintained on an extracellular matrix produced by bovine corneal endothelial cells in a defined serum-free medium. The hormones released in the culture medium were analyzed by high pressure gel chromatography. Three fractions of tumor TSH were found, with respective apparent mol wts of 45,000 (11%), 28,000 (70%), and 20,000 (19%). Tumoral PRL eluted as a single peak of apparent mol wt of 24,000. Pharmacological studies of TSH, TSH-alpha, and PRL release using thyroid hormones (T3), dopamine agonist (bromocriptine), TRH, and cholera toxin yielded the following results: 1) T3 after 3 days of incubation produced a dose-dependent inhibition of TSH, TSH-alpha, and PRL release. Maximal inhibition (81%) was obtained at 10(-9) M and half-maximal inhibition at 4-6 X 10(-11) M. 2) Bromocriptine produced rapid and partial inhibition of hormone release. Maximal inhibition (51%) was obtained at 10(-8) M and half-maximal inhibition at 5 X 10(-10) M. 3) TRH at 10(-8) M concentration significantly stimulated PRL release but it had no effect on TSH release. 4) Adenylate cyclase activation by 10(-11) M cholera toxin increased TSH (152%), TSH-alpha (150%), and PRL (220%). Immunohistochemical analysis of serial 2 micron sections of the tumor showed that: 1) TSH-alpha immunoreactive cells were the most numerous, 2) TSH-beta positive cells were always positive for TSH-alpha, 3) PRL immunoreactivity was found either uniquely in some cells and colocalized with TSH-alpha immunoreactivity in other cells. However, by electron microscopy, the tumor cells were thyrotrophs. These data indicate that in this patient's tumor: 1) cells secreting TSH were responsive in vitro to near physiological concentrations of thyroid hormones. 2) The colocalization of PRL and TSH-alpha immunoreactivities in some cells raises the possibility either of fusion of differentiated pituitary cells synthesizing distinct hormones or of transformation of less differentiated multipotential pituitary cells.
一名43岁女性,既往曾行甲状腺次全切除术,因垂体腺瘤分泌促甲状腺激素(TSH)、α-促甲状腺素(TSH-α)和催乳素(PRL)而出现甲状腺功能亢进和闭经-溢乳。她的血清总甲状腺素(T4)浓度为14微克/分升;三碘甲状腺原氨酸(T3)为5.7纳克/毫升,TSH为19 - 33微单位/毫升。TRH刺激或T3抑制后血清TSH无变化。基础血浆PRL水平为19 - 27纳克/毫升,TRH刺激后血浆PRL增加一倍。通过经蝶窦手术切除的一个900毫克垂体瘤进行细胞培养研究。分散后,肿瘤细胞在由牛角膜内皮细胞产生的细胞外基质上,于特定无血清培养基中培养。通过高压凝胶色谱法分析培养基中释放的激素。发现肿瘤TSH有三个组分,其表观分子量分别为45,000(11%)、28,000(70%)和20,000(19%)。肿瘤PRL洗脱为一个表观分子量为24,000的单峰。使用甲状腺激素(T3)、多巴胺激动剂(溴隐亭)、TRH和霍乱毒素对TSH、TSH-α和PRL释放进行药理学研究,结果如下:1)孵育3天后,T3产生剂量依赖性抑制TSH、TSH-α和PRL释放。在10⁻⁹摩尔/升时获得最大抑制(81%),在4 - 6×10⁻¹¹摩尔/升时获得半数最大抑制。2)溴隐亭产生快速且部分抑制激素释放。在10⁻⁸摩尔/升时获得最大抑制(51%),在5×10⁻¹⁰摩尔/升时获得半数最大抑制。3)浓度为10⁻⁸摩尔/升的TRH显著刺激PRL释放,但对TSH释放无影响。4)10⁻¹¹摩尔/升霍乱毒素激活腺苷酸环化酶使TSH增加(152%)、TSH-α增加(150%)和PRL增加(220%)。对肿瘤连续2微米切片进行免疫组织化学分析显示:(1)TSH-α免疫反应性细胞数量最多;(2)TSH-β阳性细胞总是TSH-α阳性;(3)PRL免疫反应性要么仅在某些细胞中发现,要么在其他细胞中与TSH-α免疫反应性共定位。然而,通过电子显微镜检查,肿瘤细胞为促甲状腺细胞。这些数据表明,在该患者的肿瘤中:(1)分泌TSH的细胞在体外对接近生理浓度的甲状腺激素有反应;(2)某些细胞中PRL和TSH-α免疫反应性的共定位增加了合成不同激素的分化垂体细胞融合或分化程度较低的多潜能垂体细胞转化的可能性。